Back

Comparative assessment of CMR-determined extracellular volume metrics in predicting adverse outcomes

29 August 2025 (08:15 - 09:00)
Organised by: Logo
Congress Presentation Part of: Cardiac magnetic resonance insights into amyloidosis imaging T1 and T2 Mapping ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Katharina Mascherbauer

Medical University of Vienna, Vienna (Austria)

7 More presentations in this session

Presentation thumbnail
Multimodality artificial intelligence-based major adverse cardiovascular events prediction in transthyretin amyloid cardiomyopathy patients
Doctor G. Baj (Bern, CH)
Abstract Slides Video
Presentation thumbnail
Prognostic impact of atrial fibrosis detected by cardiac magnetic resonance in patients affected by cardiac amyloidosis
Doctor M. Dicorato (Bari, IT)
Abstract Slides Video
Presentation thumbnail
RGAN-Driven T1 Map Synthesis from OS-CMR: a step toward AI-assisted amyloidosis diagnosis
Doctor F. Lotfikazemi (Montreal, CA)
Abstract Slides Video
Presentation thumbnail
Brain amyloid accumulation in patients with transthyretin amyloid cardiomyopathy: a pilot study
Doctor M. Ungericht (Innsbruck, AT)
Abstract Slides Video
Presentation thumbnail
Feature tracking-cardiovascular magnetic resonance to predict major adverse cardiovascular events in patients with cardiac amyloidosis
Doctor M. Dicorato (Bari, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiac magnetic resonance insights into amyloidosis imaging

The Event

Event poster

ESC Congress 2025

29 August 2025 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Comparative assessment of extracellular volume metrics in predicting adverse outcomes in patients with transthyretin amyloid cardiomyopathy
thumbnail
Congress Presentation
Incremental prognostic value of CT-derived extracellular volume in severe aortic stenosis
thumbnail
Congress Presentation
Extra-cellular volume fraction analysis on cardiac CT is useful for predicting the prognosis of hypertrophic cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources